A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PXT3003 IN CHARCOT- MARIE-TOOTH TYPE 1A (CMT1A)

Registry ID

CLN-PXT3003-06

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PHARNEXT

Start date

2022-06-09

Completion date

2024-03-15

Last update

2021-03-04

Conditions

• CHARCOT-MARIE-TOOTH DISEASE TYPE 1A

Related clinical trials

• A FIRST-IN-HUMAN, MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF EDK060 IN ADULTS WITH CHARCOT-MARIE TOOTH TYPE 1A (CMT1A)
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFECTS OF ACE-083 IN PATIENTS WITH FSHD PREVIOUSLY ENROLLED IN STUDY A083-02 AND IN PATIENTS WITH CMT DISEASE TYPES 1 AND X PREVIOUSLY ENROLLED IN STUDY A083-03
• INTERNATIONAL, MULTI-CENTER, DOUBLE BLIND 9-MONTH FOLLOW-UP EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND TOLERABILITY OF PXT3003 IN PATIENTS WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 1A

View on source registry